Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT05672199 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05672199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05672199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Terminated
Start date
April 28, 2023
Completion date
October 31, 2024
Enrollment
25 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis